Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,513 JPY | -0.79% | -1.23% | -9.73% |
Sales 2024 | 1,604B 10.4B 820B | Sales 2025 * | 1,661B 10.77B 849B | Capitalization | 2,734B 17.74B 1,398B |
---|---|---|---|---|---|
Net income 2024 | 17.04B 111M 8.72B | Net income 2025 * | 89.55B 581M 45.79B | EV / Sales 2024 | 1.84 x |
Net Debt 2024 * | 503B 3.27B 257B | Net Debt 2025 * | 512B 3.32B 262B | EV / Sales 2025 * | 1.95 x |
P/E ratio 2024 |
173
x | P/E ratio 2025 * |
30.6
x | Employees | 14,484 |
Yield 2024 |
4.26% | Yield 2025 * |
4.92% | Free-Float | 98.83% |
Latest transcript on Astellas Pharma Inc.
1 day | -0.20% | ||
1 week | -1.23% | ||
Current month | +0.53% | ||
1 month | +4.86% | ||
3 months | -9.13% | ||
6 months | -13.10% | ||
Current year | -9.73% |
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 31/03/86 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | 10-31 |
Kenji Yasukawa
CHM | Chairman | 63 | 31/03/86 |
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 31/05/21 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 31/05/17 |
Kenji Yasukawa
CHM | Chairman | 63 | 31/03/86 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 19 M€ | +11.65% | ||
2.09% | 240 M€ | +15.33% | ||
2.01% | 60 M€ | +21.20% | ||
1.99% | 10 M€ | +15.19% | - |
Date | Price | Change | Volume |
---|---|---|---|
16/05/24 | 1,513 | -0.79% | 2 000 400 |
15/05/24 | 1,525 | +0.26% | 4,901,000 |
14/05/24 | 1,521 | +0.70% | 6,123,400 |
13/05/24 | 1,510 | -1.11% | 4,597,000 |
10/05/24 | 1,528 | -0.88% | 6,638,000 |
Delayed Quote Japan Exchange, May 16, 2024 at 02:59 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.73% | 17.43B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- 4503 Stock